Study of MEDI0618 for episodic migraine
Part of Brain & nervous system clinical trials.
This trial tests a new medicine, MEDI0618, against a placebo for people with episodic migraine. The goal is to see if MEDI0618 is safe and effective at reducing migraine days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You weigh at least 40 kg (88 lbs) and have a BMI of 18 or higher.
- You have had migraines for at least 1 year, starting before age 50.
- You have had 4 to 14 migraine days per month in the last 3 months.
- You have tried at least 2 different migraine prevention medicines that did not work well.
- You are not pregnant, not planning pregnancy, and use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at ways to help children and teens with migraine headaches by testing a care approach that includes access to evidence-based treatment. It may help if your child has frequent migraine headaches and is starting (or not already on) certain migraine-preventive medicines.
This study tests an investigational medication called NB001 for treating migraine attacks as they happen. If you have frequent migraines, this treatment might help reduce the severity or shorten the duration of your attacks.
This trial tests a substance that activates adrenomedullin receptors, which may be a new way to treat migraines. It may help people who have migraines without aura and aren't on preventive migraine medications.
This study tests new ways to monitor how well preventive migraine treatments are working. It is for people with chronic migraine who may be starting or already using preventive medications.
This study tests an add-on migraine medicine (eptinezumab) given in the emergency room to quickly relieve a migraine attack, in addition to the usual care. It aims to see if this approach reduces pain and prevents the migraine from coming back.
This study tests a new inhaled powder form of a migraine medication called dihydroergotamine (DHE) to see if it safely and effectively stops migraine attacks. If you have frequent migraines, this trial might offer you a new treatment option to try.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.